Review Article | Published:

Chimeric antigen receptor T-cell therapy — assessment and management of toxicities

Nature Reviews Clinical Oncology volume 15, pages 4762 (2018) | Download Citation

Abstract

Immunotherapy using T cells genetically engineered to express a chimeric antigen receptor (CAR) is rapidly emerging as a promising new treatment for haematological and non-haematological malignancies. CAR-T-cell therapy can induce rapid and durable clinical responses, but is associated with unique acute toxicities, which can be severe or even fatal. Cytokine-release syndrome (CRS), the most commonly observed toxicity, can range in severity from low-grade constitutional symptoms to a high-grade syndrome associated with life-threatening multiorgan dysfunction; rarely, severe CRS can evolve into fulminant haemophagocytic lymphohistiocytosis (HLH). Neurotoxicity, termed CAR-T-cell-related encephalopathy syndrome (CRES), is the second most-common adverse event, and can occur concurrently with or after CRS. Intensive monitoring and prompt management of toxicities is essential to minimize the morbidity and mortality associated with this potentially curative therapeutic approach; however, algorithms for accurate and consistent grading and management of the toxicities are lacking. To address this unmet need, we formed a CAR-T-cell-therapy-associated TOXicity (CARTOX) Working Group, comprising investigators from multiple institutions and medical disciplines who have experience in treating patients with various CAR-T-cell therapy products. Herein, we describe the multidisciplinary approach adopted at our institutions, and provide recommendations for monitoring, grading, and managing the acute toxicities that can occur in patients treated with CAR-T-cell therapy.

Key points

  • Chimeric antigen receptor (CAR)-T-cell therapy is a promising approach for the treatment of refractory malignancies, but is associated with unique acute toxicities that need specialized monitoring and management

  • Cytokine-release syndrome (CRS) and CAR-T-cell-related encephalopathy syndrome (CRES) are the most-common toxicities observed after CAR-T-cell therapy and, rarely, CRS can evolve into fulminant haemophagocytic lymphohistiocytosis (HLH)

  • Intensive monitoring, accurate grading, and prompt management of toxicities with aggressive supportive care, anti-IL-6 therapy, and/or corticosteroids for severe cases could reduce the morbidity and mortality associated with CAR-T-cell therapy

  • The guidelines proposed could also be used for grading and management of toxicities associated with other redirected-T-cell therapies, such as TCR-gene therapies and bispecific T-cell-engaging antibody (BiTE) therapies

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    & Adoptive cell transfer as personalized immunotherapy for human cancer. Science 348, 62–68 (2015).

  2. 2.

    , & Adoptive cellular therapy: a race to the finish line. Sci. Transl Med. 7, 280ps7 (2015).

  3. 3.

    et al. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood 116, 4099–4102 (2010).

  4. 4.

    , , , & Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N. Engl. J. Med. 365, 725–733 (2011).

  5. 5.

    et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N. Engl. J. Med. 368, 1509–1518 (2013).

  6. 6.

    et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci. Transl Med. 5, 177ra138 (2013).

  7. 7.

    et al. Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study. Blood 122, 2965–2973 (2013).

  8. 8.

    et al. Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation. Blood 122, 4129–4139 (2013).

  9. 9.

    et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N. Engl. J. Med. 371, 1507–1517 (2014).

  10. 10.

    et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci. Transl Med. 6, 224ra225 (2014).

  11. 11.

    et al. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J. Clin. Oncol. 33, 540–549 (2015).

  12. 12.

    et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet 385, 517–528 (2015).

  13. 13.

    et al. Chimeric antigen receptor T cells against CD19 for multiple myeloma. N. Engl. J. Med. 373, 1040–1047 (2015).

  14. 14.

    et al. Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia. Blood 127, 1117–1127 (2016).

  15. 15.

    et al. Allogeneic T cells that express an anti-CD19 chimeric antigen receptor induce remissions of B-cell malignancies that progress after allogeneic hematopoietic stem-cell transplantation without causing graft-versus-host disease. J. Clin. Oncol. 34, 1112–1121 (2016).

  16. 16.

    et al. Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells. J. Clin. Invest. 126, 3363–3376 (2016).

  17. 17.

    et al. CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients. J. Clin. Invest. 126, 2123–2138 (2016).

  18. 18.

    et al. Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells. Sci. Transl Med. 8, 355ra116 (2016).

  19. 19.

    et al. Durable molecular remissions in chronic lymphocytic leukemia treated with CD19-specific chimeric antigen receptor-modified T cells after failure of ibrutinib. J. Clin. Oncol. (2017).

  20. 20.

    et al. Lymphoma remissions caused by anti-CD19 Chimeric antigen receptor t cells are associated with high serum interleukin-15 levels. J. Clin. Oncol. 35, 1803–1813 (2017).

  21. 21.

    & Exploiting the curative potential of adoptive T-cell therapy for cancer. Immunol. Rev. 257, 56–71 (2014).

  22. 22.

    et al. B-Cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood 119, 2709–2720 (2012).

  23. 23.

    et al. Phase 1 results of ZUMA-1: a multicenter study of KTE-C19 anti-CD19 CAR T Cell therapy in refractory aggressive lymphoma. Mol. Ther. 25, 285–295 (2017).

  24. 24.

    et al. KTE-C19 (anti-CD19 CAR T cells) induces complete remissions in patients with refractory diffuse large B-cell lymphoma (DLBCL): results from the pivotal phase 2 ZUMA-1 [abstract]. Blood 128, LBA-6 (2016).

  25. 25.

    et al. Analysis of a Global registration trial of the efficacy and safety of CTL019 in pediatric and young adults with relapsed/refractory acute lymphoblastic leukemia (ALL) [abstract]. Blood 128, 221 (2016).

  26. 26.

    et al. Global pivotal phase 2 trial of the CD19-targeted therapy CTL019 in adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) — an interim analysis [abstract]. Hematol. Oncol. 35 (Suppl. S2), 27 (2017).

  27. 27.

    et al. Axicabtagene ciloleucel (Axi-cel; KTE-C19) in patients with refractory aggressive non-Hodgkin lymphomas (NHL): primary results of the pivotal trial ZUMA-1 [abstract]. Hematol. Oncol. 35 (Suppl. S2), 28 (2017).

  28. 28.

    et al. High CR rates in relapsed/refractory (R/R) aggressive B-NHL treated with the CD19-directed CAR T cell product JCAR017 (TRANSCEND NHL 001) [abstract]. Hematol. Oncol. 35 (Suppl. S2), 138 (2017).

  29. 29.

    et al. T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma. Blood 128, 1688–1700 (2016).

  30. 30.

    et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood 124, 188–195 (2014).

  31. 31.

    & Toxicities of chimeric antigen receptor T cells: recognition and management. Blood 127, 3321–3330 (2016).

  32. 32.

    , , & Managing cytokine release syndrome associated with novel T cell-engaging therapies. Cancer J. 20, 119–122 (2014).

  33. 33.

    et al. Predominant cerebral cytokine release syndrome in CD19-directed chimeric antigen receptor-modified T cell therapy. J. Hematol. Oncol. 9, 70 (2016).

  34. 34.

    et al. Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Cancer Discov. 6, 664–679 (2016).

  35. 35.

    et al. Tocilizumab-refractory cytokine release syndrome (CRS) triggered by chimeric antigen receptor (CAR)-transduced T cells may have distinct cytokine profiles compared to typical CRS. Blood 128, 3358 (2016).

  36. 36.

    et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J. Clin. Oncol. 29, 917–924 (2011).

  37. 37.

    et al. PD-L1 blockade effectively restores strong graft-versus-leukemia effects without graft-versus-host disease after delayed adoptive transfer of T-cell receptor gene-engineered allogeneic CD8+ T cells. Blood 117, 1030–1041 (2011).

  38. 38.

    et al. CD19-CAR engineered NK-92 cells are sufficient to overcome NK cell resistance in B-cell malignancies. J. Cell. Mol. Med. 20, 1287–1294 (2016).

  39. 39.

    et al. CAR-engineered NK cells targeting wild-type EGFR and EGFRvIII enhance killing of glioblastoma and patient-derived glioblastoma stem cells. Sci. Rep. 5, 11483 (2015).

  40. 40.

    et al. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science 321, 974–977 (2008).

  41. 41.

    et al. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. Lancet Oncol. 16, 57–66 (2015).

  42. 42.

    et al. Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy. Blood 121, 5154–5157 (2013).

  43. 43.

    U.S. Department of Health & Human Services. Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0 (2010).

  44. 44.

    et al. Refractory cytokine release syndrome in recipients of chimeric antigen receptor (CAR) T cells. Blood 124, 2296–2296 (2014).

  45. 45.

    IL-6 trans-signaling via the soluble IL-6 receptor: importance for the pro-inflammatory activities of IL-6. Int. J. Biol. Sci. 8, 1237–1247 (2012).

  46. 46.

    , , & The pro- and anti-inflammatory properties of the cytokine interleukin-6. Biochim. Biophys. Acta 1813, 878–888 (2011).

  47. 47.

    et al. Measuring IL-6 and sIL-6R in serum from patients treated with tocilizumab and/or siltuximab following CAR T cell therapy. J. Immunol. Methods 434, 1–8 (2016).

  48. 48.

    , & Tocilizumab for rheumatoid arthritis. Cochrane Database of Syst. Rev. CD008331 (2010).

  49. 49.

    et al. FDA approval: siltuximab for the treatment of patients with multicentric Castleman disease. Clin. Cancer Res. 21, 950–954 (2015).

  50. 50.

    , , & Toxicity and management in CAR T-cell therapy. Mol. Ther. Oncolyt. 3, 16011 (2016).

  51. 51.

    et al. Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family. Int. Immunopharmacol. 5, 1731–1740 (2005).

  52. 52.

    , & CNTO 328, a monoclonal antibody to IL-6, inhibits human tumor-induced cachexia in nude mice. Int. J. Cancer. 111, 592–595 (2004).

  53. 53.

    et al. Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. Blood 112, 3959–3964 (2008).

  54. 54.

    , , , & Novel mechanism for inhibition of human T cells by glucocorticoids. Glucocorticoids inhibit signal transduction through IL-2 receptor. J. Immunol. 151, 4081–4089 (1993).

  55. 55.

    et al. Prednisone increases apoptosis in in vitro activated human peripheral blood T lymphocytes. Clin. Exp. Immunol. 103, 482–490 (1996).

  56. 56.

    et al. Effects of dexamethasone on the profile of cytokine secretion in human whole blood cell cultures. Regul. Pept. 73, 59–65 (1998).

  57. 57.

    et al. Cytomegalovirus reactivation following allogeneic stem cell transplantation is associated with the presence of dysfunctional antigen-specific CD8+ T cells. Blood 100, 3690–3697 (2002).

  58. 58.

    & Properties of four acute phase proteins: C-reactive protein, serum amyloid A protein, α1-acid glycoprotein, and fibrinogen. Semin. Arthritis Rheum. 20, 129–147 (1990).

  59. 59.

    & C-Reactive protein: a critical update. J. Clin. Invest. 111, 1805–1812 (2003).

  60. 60.

    & IL-6 pathway in the liver: from physiopathology to therapy. J. Hepatol. 64, 1403–1415 (2016).

  61. 61.

    et al. Sustained remissions following chimeric antigen receptor modified T cells directed against CD19 (CTL019) in patients with relapsed or refractory CD19+ lymphomas. Blood 126, 183–183 (2015).

  62. 62.

    et al. Biomarkers associated with neurotoxicity in adult patients with relapsed or refractory B-ALL (R/R B-ALL) treated with CD19 CAR T cells [abstract]. J. Clin. Oncol. 35, (15 Suppl.), 3019 (2017).

  63. 63.

    et al. Cytokine release syndrome (CRS) and neurotoxicity (NT) after CD19-specific chimeric antigen receptor- (CAR-) modified T cells [abstract]. J. Clin. Oncol. 35, (15 Suppl.), 3020 (2017).

  64. 64.

    & Driving gene-engineered T cell immunotherapy of cancer. Cell Res. 27, 38–58 (2017).

  65. 65.

    , & Nonconvulsive status epilepticus in adults — insights into the invisible. Nat. Rev. Neurol. 12, 281–293 (2016).

  66. 66.

    et al. Nonconvulsive status epilepticus: Epilepsy Research Foundation workshop reports. Epileptic Disord. 7, 253–296 (2005).

  67. 67.

    Levetiracetam: a novel antiepileptic drug. Pharmacotherapy 21, 1375–1388 (2001).

  68. 68.

    et al. Chronic valproate or levetiracetam treatment does not influence cytokine levels in humans. Seizure 23, 666–669 (2014).

  69. 69.

    Reuters. Juno ends development of high-profile leukemia drug after deaths. Reuters (2017).

  70. 70.

    Kite reports cerebral edema death in ZUMA-1 CAR T-cell trial. OncLive (2017).

  71. 71.

    et al. HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr. Blood Cancer 48, 124–131 (2007).

  72. 72.

    , , , & Adult haemophagocytic syndrome. Lancet 383, 1503–1516 (2014).

  73. 73.

    , , & An animal model of hemophagocytic lymphohistiocytosis (HLH): CD8+ T cells and interferon gamma are essential for the disorder. Blood 104, 735–743 (2004).

  74. 74.

    , , , & How I treat hemophagocytic lymphohistiocytosis. Blood 118, 4041–4052 (2011).

  75. 75.

    et al. Malignancy-associated hemophagocytic lymphohistiocytosis in adults: Relation to hemophagocytosis, characteristics, and outcomes. Cancer 122, 2857–2866 (2016).

  76. 76.

    & Malignancy-associated haemophagocytic lymphohistiocytosis in adults. Lancet Oncol. 18, 169–171 (2017).

  77. 77.

    & How I treat hemophagocytic lymphohistiocytosis in the adult patient. Blood 125, 2908–2914 (2015).

  78. 78.

    et al. A novel targeted approach to the treatment of hemophagocytic lymphohistiocytosis (HLH) with an anti-interferon gamma (IFNγ) monoclonal antibody (mAb), NI-0501: first results from a pilot phase 2 study in children with primary HLH [abstract]. Blood 126, LBA-3 (2015).

  79. 79.

    & Improving the safety of T-Cell therapies using an inducible caspase-9 gene. Exp. Hematol. 44, 1013–1019 (2016).

  80. 80.

    , & Driving CAR T-cells forward. Nat. Rev. Clin. Oncol. 13, 370–383 (2016).

  81. 81.

    et al. Inducible apoptosis as a safety switch for adoptive cell therapy. N. Engl. J. Med. 365, 1673–1683 (2011).

  82. 82.

    et al. Characterization of CD20-transduced T lymphocytes as an alternative suicide gene therapy approach for the treatment of graft-versus-host disease. Hum. Gene Ther. 15, 63–76 (2004).

  83. 83.

    et al. A transgene-encoded cell surface polypeptide for selection. in vivo tracking, and ablation of engineered cells. Blood 118, 1255–1263 (2011).

  84. 84.

    et al. A highly compact epitope-based marker/suicide gene for easier and safer T-cell therapy. Blood 124, 1277–1287 (2014).

  85. 85.

    et al. A Fas-based suicide switch in human T cells for the treatment of graft-versus-host disease. Blood 97, 1249–1257 (2001).

  86. 86.

    et al. A Tet-on inducible system for controlling CD19-chimeric antigen receptor expression upon drug administration. Cancer Immunol. Res. 4, 658–668 (2016).

  87. 87.

    , , & Chimeric Antigen receptors modified T-cells for cancer therapy. J. Natl Cancer Inst. 108, djv439 (2016).

  88. 88.

    et al. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol. Ther. 18, 843–851 (2010).

  89. 89.

    et al. Human epidermal growth factor receptor 2 (HER2)-specific chimeric antigen receptor-modified T cells for the immunotherapy of HER2-positive sarcoma. J. Clin. Oncol. 33, 1688–1696 (2015).

  90. 90.

    et al. T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. Mol. Ther. 19, 620–626 (2011).

  91. 91.

    et al. Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity. Mol. Ther. 21, 904–912 (2013).

  92. 92.

    et al. Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience. J. Clin. Oncol. 24, e20–e22 (2006).

  93. 93.

    et al. T cells expressing chimeric antigen receptors can cause anaphylaxis in humans. Cancer Immunol. Res. 1, 26–31 (2013).

  94. 94.

    , , , & Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: case report of an unforeseen adverse event in a phase I clinical trial. Mol. Ther. 18, 666–668 (2010).

  95. 95.

    et al. Chimeric antigen receptor modified T cells directed against CD19 (CTL019) in patients with poor prognosis, relapsed or refractory CD19+ follicular lymphoma: prolonged remissions relative to antecedent therapy [abstract]. Blood 128, 1100 (2016).

  96. 96.

    et al. A phase 2 multicenter trial of KTE-C19 (anti-CD19 CAR T Cells) in patients with chemorefractory primary mediastinal B-cell lymphoma (PMBCL) and transformed follicular lymphoma (TFL): interim results from ZUMA-1 [abstract]. Blood 128, 998 (2016).

  97. 97.

    et al. Vasopressin versus norepinephrine infusion in patients with septic shock. N. Engl. J. Med. 358, 877–887 (2008).

  98. 98.

    Swelling of the optic nerve head: a staging scheme. J. Neurol. Neurosurg. Psychiatry 45, 13–18 (1982).

Download references

Acknowledgements

The work of S.S.N. is supported by The University of Texas MD Anderson Cancer Center Support Grant (P30 CA016672) from the US Department of Health & Human Services, National Institutes of Health, and by generous philanthropic contributions to the University of Texas MD Anderson Moon Shots Program.

Author information

Affiliations

  1. Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030, USA.

    • Sattva S. Neelapu
    • , Jason Westin
    •  & Sherry Adkins
  2. Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030, USA.

    • Sudhakar Tummala
    • , Monica E. Loghin
    •  & John F. de Groot
  3. Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030, USA.

    • Partow Kebriaei
    • , Katayoun Rezvani
    •  & Elizabeth J. Shpall
  4. Department of Leukemia, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030, USA.

    • William Wierda
    • , Nitin Jain
    •  & Naval Daver
  5. Department of Critical Care, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030, USA.

    • Cristina Gutierrez
  6. Department of Blood and Marrow Transplantation and Cellular Immunotherapy, Moffitt Cancer Center, 12902 USF Magnolia Drive, Tampa, Florida 33613, USA.

    • Frederick L. Locke
  7. Adult Stem Cell Transplant Program, Sylvester Comprehensive Cancer Center, University of Miami, 1475 Northwest 12 th Avenue, Miami, Florida 33136, USA.

    • Krishna V. Komanduri
  8. Division of Hematology, Mayo Clinic, 200 First Street South West, Rochester, Minnesota 55905, USA.

    • Yi Lin
  9. Division of Pharmacy, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030, USA.

    • Alison M. Gulbis
  10. Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030, USA.

    • Suzanne E. Davis
    •  & Patrick Hwu

Authors

  1. Search for Sattva S. Neelapu in:

  2. Search for Sudhakar Tummala in:

  3. Search for Partow Kebriaei in:

  4. Search for William Wierda in:

  5. Search for Cristina Gutierrez in:

  6. Search for Frederick L. Locke in:

  7. Search for Krishna V. Komanduri in:

  8. Search for Yi Lin in:

  9. Search for Nitin Jain in:

  10. Search for Naval Daver in:

  11. Search for Jason Westin in:

  12. Search for Alison M. Gulbis in:

  13. Search for Monica E. Loghin in:

  14. Search for John F. de Groot in:

  15. Search for Sherry Adkins in:

  16. Search for Suzanne E. Davis in:

  17. Search for Katayoun Rezvani in:

  18. Search for Patrick Hwu in:

  19. Search for Elizabeth J. Shpall in:

Contributions

S.S.N. and S.T. contributed equally to this article, and wrote the manuscript. S.S.N., S.T., N.J., N.D., A.M.G., and S.A. contributed to researching data for article. All authors contributed to discussions of content, to the development of the proposed guidelines, and to review/editing of the manuscript before submission.

Competing interests

S.S.N. has received research support from Bristol-Myers Squibb, Celgene, Cellectis, Kite Pharma, Merck, and Poseida Therapeutics. S.S.N. has also served as a consultant and/or Scientific Advisory Board member for Celgene, Kite Pharma, Merck, and Novartis. S.T. served as a Scientific Advisory Board member for Kite Pharma. F.L.L. has served as a Scientific Advisory Board member for Kite Pharma, and as a Consultant to Cellular Biomedicine Group. K.V.K. has served as a scientific advisor to and has received research funding from Juno Therapeutics and Kite Pharma. Y.L. has received research funding from Janssen. N.J. has received research support from Abbvie, ADC Therapeutics, Bristol-Myers Squibb, Celgene, Genentech, Incyte, Pharmacyclics, Pfizer, Seattle Genetics, Servier, and Verastem. N.J. has also served on the advisory board and received honorarium from Adaptive Biotechnologies, ADC Therapeutics, Novartis, Novimmune, Pharmacyclics, Pfizer, Servier, and Verastem. N.D. has received research support from Bristol-Myers Squibb, Daichi-Sanky, Incyte, Karyopharm, Pfizer, and Sunesis. N.D. has also received served as a consultant for Incyte, Jazz, Karyopharm, Novartis, Otsuka, Pfizer, and Sunesis. J.W. has received research funding and served on the Advisory Boards for Kite Pharma and Novartis. J.F.d.G. has received research support from Astrazeneca, Deciphera Pharmaceuticals, Eli Lilly, EMD-Serono, Mundipharma, Novartis, Sanofi-Aventis. J.F.d.G. has also served as a consultant or Advisory Board member for AbbVie, Astrazeneca, Celldex, Deciphera Pharmaceuticals, FivePrime Therapeutics, Foundation Medicine, Genentech, Insys Therapeutics, Kadmon, Merck, Novartis, and Novogen. J.F.d.G. is a stock owner of Gilead and Ziopharm Oncology, and his spouse is employed by Ziopharm Oncology. S.A. served as an Advisory Board member for Kite Pharma. K.R. is on the Independent Data Monitoring Committee for Kiadis Pharma. The other authors declare no competing interests.

Corresponding author

Correspondence to Sattva S. Neelapu.

Supplementary information

PDF files

  1. 1.

    Supplementary information S1 (table)

    Comparison of tocilizumab and siltuximab

  2. 2.

    Supplementary information S2 (table)

    Example customized tracking tool for toxicities of CAR-T-cell therapy in EHRs

About this article

Publication history

Published

DOI

https://doi.org/10.1038/nrclinonc.2017.148

Further reading